Although study 2 was designed with the overall intent to provide safety and PK data that would support patient studies in AD, the first part of the study was designed to address the potential cytochrome P450 3A4 (CYP3A4) DDI liability noted above, as this had the potential to negatively impact on the overall developability of the molecule. Here, CYP3A4 is linked to Alzheimer disease.